Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01) Clinical Trials Not Allowed

Archived

Food and Drug Administration

Description

The purpose of this funding opportunity is to incorporate social outcomes (quality of life, untreated pain, etc.) and cost effectiveness into FDA's existing model and policy analysis tool. Work resulting from this funding opportunity should provide more holistic insight into the opioid crisis and enhance decision makers' ability to propose and consider policy options. Such work will require the integration of new structural components, new data, and new analyses into the model. Given the paucity of data surrounding opioids interventions, this effort will also require studies to collect information about the costs, social outcomes, and other details associated with potential policies.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

Shashi Malhotra <br/>Grants Management Specialist <br/>Phone 2404027592
shashi.malhotra@fda.hhs.gov

Key dates & funding
  • PostedMar 16, 2020
  • ClosesMay 18, 2020
  • Award floor$500,000
  • Award ceiling$1,000,000
  • Expected awards1
  • CFDA93.103

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro